Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer : a collaborative analysis of 20 prospective studies and Mendelian randomization analysis

Title: Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer : a collaborative analysis of 20 prospective studies and Mendelian randomization analysis
Authors: Watts, Eleanor L.; Perez-Cornago, Aurora; Fensom, Georgina K.; Smith-Byrne, Karl; Noor, Urwah; Andrews, Colm D.; Gunter, Marc J.; Holmes, Michael V.; Martin, Richard M.; Tsilidis, Konstantinos K.; Albanes, Demetrius; Barricarte, Aurelio; Bueno-De-Mesquita, H. Bas; Cohn, Barbara A.; Deschasaux-Tanguy, Melanie; Dimou, Niki L.; Ferrucci, Luigi; Flicker, Leon; Freedman, Neal D.; Giles, Graham G.; Giovannucci, Edward L.; Haiman, Christopher A.; Hankey, Graham J.; Holly, Jeffrey M. P.; Huang, Jiaqi; Huang, Wen-Yi; Hurwitz, Lauren M.; Kaaks, Rudolf; Kubo, Tatsuhiko; Le Marchand, Loic; Macinnis, Robert J.; Männistö, Satu; Metter, E. Jeffrey; Mikami, Kazuya; Mucci, Lorelei A.; Olsen, Anja W.; Ozasa, Kotaro; Palli, Domenico; Penney, Kathryn L.; Platz, Elizabeth A.; Pollak, Michael N.; Roobol, Monique J.; Schaefer, Catherine A.; Schenk, Jeannette M.; Stattin, Pär; Tamakoshi, Akiko; Thysell, Elin; Tsai, Chiaojung Jillian; Touvier, Mathilde; Van Den Eeden, Stephen K.; Weiderpass, Elisabete; Weinstein, Stephanie J.; Wilkens, Lynne R.; Yeap, Bu B.; Allen, Naomi E.; Key, Timothy J.; Travis, Ruth C.; The PRACTICAL Consortium, CRUK, BPC3, CAPS, PEGASUS
Publisher Information: Umeå universitet, Patologi; Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France; Section of Nutrition and Metabolism, International Agency for Research on Cancer, Lyon, France; Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Medical Research Council Population Health Research Unit, University of Oxford, Oxford, United Kingdom; Department of Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom; MRC Integrative Epidemiology Unit (IEU), Bristol Medical School, University of Bristol, Bristol, United Kingdom; National Institute for Health Research (NIHR) Bristol Biomedical Research Centre, Univ. Hospitals Bristol NHS Found. Trust and Weston NHS Foundation Trust and University of Bristol, Bristol, United Kingdom; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom; Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, MD, Bethesda, United States; Group of Epidemiology of Cancer and Other Chronic Diseases, Navarra Public Health Institute, Pamplona, Spain; Group of Epidemiology of Cancer and Other Chronic Diseases, Navarra Institute for Health Research (IdiSNA), Pamplona, Spain; CIBER Epidemiology and Public Health CIBERESP, Madrid, Spain; Centre for Nutrition, Prevention and Health Services, National Institute for Public Health and the Environment (RIVM), Utrecht, Netherlands; Child Health and Development Studies, Public Health Institute, CA, Berkeley, United States; Sorbonne Paris Nord University, Nutritional Epidemiology Research Team, Epidemiology and Statistics Research Center, University of Paris, Bobigny, France; National Institute on Aging, MD, Baltimore, United States; WA Centre for Health & Ageing, Medical School, University of Western Australia, WA, Perth, Australia; Western Australian Centre for Health and Ageing, University of Western Australia, WA, Perth, Australia; Cancer Epidemiology Division, Cancer Council Victoria, VIC, Melbourne, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, VIC, Melbourne, Australia; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, VIC, Melbourne, Australia; Department of Epidemiology, Harvard T.H. Chan School of Public Health, MA, Boston, United States; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, MA, Boston, United States; Department of Nutrition, Harvard T.H. Chan School of Public Health, MA, Boston, United States; Department of Preventive Medicine, Center for Genetic Epidemiology, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, CA, Los Angeles, United States; WA Centre for Health & Ageing, Medical School, University of Western Australia, WA, Perth, Australia; IGFs & Metabolic Endocrinology Group, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, MD, Bethesda, United States; National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, Department of Metabolism and Endocrinology, Second Xiangya Hospital of Central South University, Changsha, Hunan, China; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Public Health and Health Policy, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; University of Hawaii, Cancer Center, HI, Honolulu, United States; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, VIC, Melbourne, Australia; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, VIC, Melbourne, Australia; Department of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland; Department of Neurology, College of Medicine, University of Tennessee Health Science Center, TN, Memphis, United States; Departmemt of Urology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan; Department of Epidemiology, Harvard T.H. Chan School of Public Health, MA, Boston, United States; Department of Public Health, Aarhus University, Aarhus, Denmark; Danish Cancer Society, Research Center, Copenhagen, Denmark; Departmemt of Epidemiology, Radiation Effects Research Foundation, Hiroshima, Japan; Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network, Florence, Italy; Department of Epidemiology, Harvard T.H. Chan School of Public Health, MA, Boston, United States; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, MA, Boston, United States; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, MD, Baltimore, United States; Departments of Medicine and Oncology, McGill University, QC, Montreal, Canada; Department of Urology, Erasmus University Medical Center, Rotterdam, Netherlands; Division of Research, Kaiser Permanente Northern California, CA, Oakland, United States; Cancer Prevention Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, WA, Seattle, United States; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden; Department of Public Health, Faculty of Medicine, Hokkaido University, Sapporo, Japan; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, NY, New York, United States; Division of Research, Kaiser Permanente Northern California, CA, Oakland, United States; Department of Urology, University of California San Francisco, CA, San Francisco, United States; Director's Office, International Agency for Research on Cancer, World Health Organization, Lyon, France; WA Centre for Health & Ageing, Medical School, University of Western Australia, WA, Perth, Australia; Department of Endocrinology and Diabetes, Fiona Stanley Hospital, WA, Perth, Australia; Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; UK Biobank Ltd, Stockport, United Kingdom
Publication Year: 2023
Collection: Umeå University: Publications (DiVA)
Subject Terms: aggressive prostate cancer; Insulin-like growth factor-I; international consortia; Mendelian randomization; prospective analysis; prostate cancer; Cancer and Oncology; Cancer och onkologi
Description: Background: Previous studies had limited power to assess the associations of circulating insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) with clinically relevant prostate cancer as a primary endpoint, and the association of genetically predicted IGF-I with aggressive prostate cancer is not known. We aimed to investigate the associations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 concentrations with overall, aggressive and early-onset prostate cancer. Methods: Prospective analysis of biomarkers using the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group dataset (up to 20 studies, 17 009 prostate cancer cases, including 2332 aggressive cases). Odds ratios (OR) and 95% confidence intervals (CI) for prostate cancer were estimated using conditional logistic regression. For IGF-I, two-sample Mendelian randomization (MR) analysis was undertaken using instruments identified using UK Biobank (158 444 men) and outcome data from PRACTICAL (up to 85 554 cases, including 15 167 aggressive cases). Additionally, we used colocalization to rule out confounding by linkage disequilibrium. Results: In observational analyses, IGF-I was positively associated with risks of overall (OR per 1 SD = 1.09: 95% CI 1.07, 1.11), aggressive (1.09: 1.03, 1.16) and possibly early-onset disease (1.11: 1.00, 1.24); associations were similar in MR analyses (OR per 1 SD = 1.07: 1.00, 1.15; 1.10: 1.01, 1.20; and 1.13; 0.98, 1.30, respectively). Colocalization also indicated a shared signal for IGF-I and prostate cancer (PP4: 99%). Men with higher IGF-II (1.06: 1.02, 1.11) and IGFBP-3 (1.08: 1.04, 1.11) had higher risks of overall prostate cancer, whereas higher IGFBP-1 was associated with a lower risk (0.95: 0.91, 0.99); these associations were attenuated following adjustment for IGF-I. Conclusions: These findings support the role of IGF-I in the development of prostate cancer, including for aggressive disease.
Document Type: article in journal/newspaper
File Description: application/pdf
Language: English
Relation: International Journal of Epidemiology, 0300-5771, 2023, 52:1, s. 71-86; PMID 35726641; ISI:000813479800001
DOI: 10.1093/ije/dyac124
Availability: http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-211993; https://doi.org/10.1093/ije/dyac124
Rights: info:eu-repo/semantics/openAccess
Accession Number: edsbas.7A73C91C
Database: BASE